DNLI
Price
$16.66
Change
-$0.06 (-0.36%)
Updated
Oct 17 closing price
Capitalization
2.44B
12 days until earnings call
EYPT
Price
$11.63
Change
+$0.08 (+0.69%)
Updated
Oct 17 closing price
Capitalization
939.16M
11 days until earnings call
Interact to see
Advertisement

DNLI vs EYPT

Header iconDNLI vs EYPT Comparison
Open Charts DNLI vs EYPTBanner chart's image
Denali Therapeutics
Price$16.66
Change-$0.06 (-0.36%)
Volume$1.37M
Capitalization2.44B
EyePoint Pharmaceuticals
Price$11.63
Change+$0.08 (+0.69%)
Volume$1.39M
Capitalization939.16M
DNLI vs EYPT Comparison Chart in %
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. EYPT commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (DNLI: $16.72 vs. EYPT: $11.55)
Brand notoriety: DNLI and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 125% vs. EYPT: 185%
Market capitalization -- DNLI: $2.44B vs. EYPT: $939.16M
DNLI [@Biotechnology] is valued at $2.44B. EYPT’s [@Biotechnology] market capitalization is $939.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 5 bearish.
  • EYPT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both DNLI and EYPT are a good buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +3.40% price change this week, while EYPT (@Biotechnology) price change was -17.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +16.02%, and the average quarterly price growth was +79.42%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.44B) has a higher market cap than EYPT($939M). EYPT YTD gains are higher at: 56.107 vs. DNLI (-18.253). EYPT has higher annual earnings (EBITDA): -172.05M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. EYPT (256M). EYPT has less debt than DNLI: EYPT (21.8M) vs DNLI (46.6M). EYPT has higher revenues than DNLI: EYPT (51.9M) vs DNLI (0).
DNLIEYPTDNLI / EYPT
Capitalization2.44B939M259%
EBITDA-521.52M-172.05M303%
Gain YTD-18.25356.107-33%
P/E RatioN/AN/A-
Revenue051.9M-
Total Cash899M256M351%
Total Debt46.6M21.8M214%
FUNDAMENTALS RATINGS
DNLI vs EYPT: Fundamental Ratings
DNLI
EYPT
OUTLOOK RATING
1..100
1865
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9191
P/E GROWTH RATING
1..100
10016
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (68) in the Pharmaceuticals Major industry is in the same range as DNLI (93) in the Biotechnology industry. This means that EYPT’s stock grew similarly to DNLI’s over the last 12 months.

EYPT's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as DNLI (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to DNLI’s over the last 12 months.

EYPT's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as DNLI (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to DNLI’s over the last 12 months.

EYPT's Price Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as DNLI (91) in the Biotechnology industry. This means that EYPT’s stock grew similarly to DNLI’s over the last 12 months.

EYPT's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIEYPT
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 10 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUXAX33.770.23
+0.69%
Auxier Focus A
ATYGX14.100.03
+0.21%
American Century International Gr Y
SSMAX10.220.02
+0.20%
SEI Small/Mid Cap Equity A (SIIT)
MRSHX26.34-0.03
-0.11%
MFS Research International R3
QISRX13.42-0.09
-0.67%
Pear Tree Polaris Intl Opps R6

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.36%
NRIX - DNLI
58%
Loosely correlated
-1.89%
ARWR - DNLI
56%
Loosely correlated
-5.54%
RGNX - DNLI
55%
Loosely correlated
-4.94%
BEAM - DNLI
55%
Loosely correlated
+0.74%
OCUL - DNLI
54%
Loosely correlated
-2.95%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+0.69%
OCUL - EYPT
62%
Loosely correlated
-2.95%
LYRA - EYPT
58%
Loosely correlated
-3.47%
ATHE - EYPT
54%
Loosely correlated
+1.24%
BEAM - EYPT
51%
Loosely correlated
+0.74%
DNLI - EYPT
48%
Loosely correlated
-0.36%
More